PL2068938T3 - Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI - Google Patents

Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI

Info

Publication number
PL2068938T3
PL2068938T3 PL07842842T PL07842842T PL2068938T3 PL 2068938 T3 PL2068938 T3 PL 2068938T3 PL 07842842 T PL07842842 T PL 07842842T PL 07842842 T PL07842842 T PL 07842842T PL 2068938 T3 PL2068938 T3 PL 2068938T3
Authority
PL
Poland
Prior art keywords
leukemia
tyrosine kinase
abl tyrosine
cmin
kinase inhibitor
Prior art date
Application number
PL07842842T
Other languages
English (en)
Inventor
Insa Gathmann
Francois-Xavier Mahon
Mathieu Molimard
Stéphane Picard
Yanfeng Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2068938(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2068938T3 publication Critical patent/PL2068938T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Ecology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL07842842T 2006-09-22 2007-09-20 Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI PL2068938T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82662206P 2006-09-22 2006-09-22
US82827806P 2006-10-05 2006-10-05
PCT/US2007/078978 WO2008036792A2 (en) 2006-09-22 2007-09-20 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
EP07842842A EP2068938B1 (en) 2006-09-22 2007-09-20 Optimization of the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitor imatinib

Publications (1)

Publication Number Publication Date
PL2068938T3 true PL2068938T3 (pl) 2011-06-30

Family

ID=39092883

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07842842T PL2068938T3 (pl) 2006-09-22 2007-09-20 Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI

Country Status (25)

Country Link
US (2) US20090281113A1 (pl)
EP (2) EP2251042A3 (pl)
JP (1) JP5735742B2 (pl)
KR (1) KR20090065512A (pl)
AT (1) ATE495761T1 (pl)
AU (1) AU2007299764B2 (pl)
BR (1) BRPI0717099A2 (pl)
CA (1) CA2662977A1 (pl)
CL (1) CL2007002725A1 (pl)
CY (1) CY1111356T1 (pl)
DE (1) DE602007012122D1 (pl)
DK (1) DK2068938T3 (pl)
HK (1) HK1133194A1 (pl)
HR (1) HRP20110250T1 (pl)
IL (1) IL197296A (pl)
MA (1) MA30786B1 (pl)
MX (1) MX2009003082A (pl)
NO (1) NO20091490L (pl)
NZ (1) NZ575113A (pl)
PL (1) PL2068938T3 (pl)
PT (1) PT2068938E (pl)
TN (1) TN2009000094A1 (pl)
TW (1) TWI398251B (pl)
WO (1) WO2008036792A2 (pl)
ZA (1) ZA200901220B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101579993B1 (ko) 2008-01-23 2015-12-23 노파르티스 아게 이마티닙을 이용한 티로신 키나제 수용체 ｋｉｔ에 의해 매개되는 증식성 질환의 치료를 최적화하는 방법
EP2370078A1 (en) 2008-12-01 2011-10-05 Novartis AG Method of optimizing the treatment of philadelphia-positive leukemia with imatinib mesylate
US20110046919A1 (en) 2009-03-02 2011-02-24 Juliesta Elaine Sylvester Method for accurate measurement of enzyme activities
FR2943418A1 (fr) * 2009-03-17 2010-09-24 Centre Nat Rech Scient Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications
EP3072964A1 (en) * 2013-11-22 2016-09-28 National Center For Child Health And Development Novel chimera gene atf7ip-pdgfrb for acute lymphoblastic leukemia
WO2017007547A1 (en) 2015-07-07 2017-01-12 Codexis, Inc. Novel p450-bm3 variants with improved activity
IT201900008808A1 (it) 2019-06-13 2020-12-13 Univ Ca Foscari Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma
CN114994213A (zh) * 2022-06-28 2022-09-02 北京赛诺浦生物技术有限公司 一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ES2391550T3 (es) 1999-04-15 2012-11-27 Bristol-Myers Squibb Company Inhibidores cíclicos de la proteína tirosina quinasa
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
JP2005522221A (ja) * 2002-04-17 2005-07-28 ノバルティス アクチエンゲゼルシャフト チロシンキナーゼ阻害剤に対する患者応答性の予測方法
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
MXPA06014247A (es) 2004-06-10 2007-03-12 Irm Llc Compuestos y composiciones como inhibidores de la proteina quinasa.
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
MY148074A (en) 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant

Also Published As

Publication number Publication date
AU2007299764A1 (en) 2008-03-27
KR20090065512A (ko) 2009-06-22
JP2010504353A (ja) 2010-02-12
BRPI0717099A2 (pt) 2013-10-15
WO2008036792A3 (en) 2008-11-13
HK1133194A1 (en) 2010-03-19
CL2007002725A1 (es) 2008-05-16
EP2068938B1 (en) 2011-01-19
IL197296A (en) 2011-11-30
EP2251042A2 (en) 2010-11-17
AU2007299764B2 (en) 2011-10-13
US20090281113A1 (en) 2009-11-12
EP2068938A2 (en) 2009-06-17
TW200822926A (en) 2008-06-01
ZA200901220B (en) 2010-02-24
DK2068938T3 (da) 2011-04-04
US20170007605A1 (en) 2017-01-12
EP2251042A3 (en) 2012-05-02
MX2009003082A (es) 2009-04-01
TN2009000094A1 (en) 2010-08-19
IL197296A0 (en) 2011-08-01
JP5735742B2 (ja) 2015-06-17
NO20091490L (no) 2009-06-15
CA2662977A1 (en) 2008-03-27
HRP20110250T1 (hr) 2011-05-31
PT2068938E (pt) 2011-03-23
DE602007012122D1 (de) 2011-03-03
TWI398251B (zh) 2013-06-11
ATE495761T1 (de) 2011-02-15
MA30786B1 (fr) 2009-10-01
RU2009114856A (ru) 2010-10-27
NZ575113A (en) 2012-03-30
WO2008036792A2 (en) 2008-03-27
CY1111356T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
HK1133194A1 (en) Optimization of the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitor imatinib
EA201400197A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
BR0311814A (pt) Método de tratar câncer empregando inibidores de cinase
EA200600920A1 (ru) Иммуносорбентные исследования крови для оценки пароксизмальных церебральных разрядов
WO2006110176A3 (en) Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
BRPI0518795A2 (pt) mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio
DK2196199T3 (da) Behandling af fantomfænomener
SG163614A1 (en) Colon cancer related gene tom34
KR20210137045A (ko) 수면 개선 방법
US8697702B2 (en) Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
RU2011122721A (ru) Способ оптимизации лечения хронического миелолейкоза ингибиторами тирозинказы abl
EA201300410A1 (ru) Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2
TW200507828A (en) Method for treatment of chemotherapy-induced diarrhea
Büchner et al. Two years of experience using stimulation rates between 800 and 5000 pps with the clarion CII implant
Rodriguez et al. AB0165 THE ROLE OF CXCL4, CXCL8 AND GDF-15 IN SYSTEMIC SCLEROSIS
Gu The effect of obstructive sleep apnea on sleep architecture and cognition in Parkinson’s disease
WO2001045690A3 (en) Use of bvdu for inhibiting the growth of hyperproliferative cells
RU2483732C2 (ru) СПОСОБ ОПТИМИЗАЦИИ ЛЕЧЕНИЯ ЛЕЙКОЗА, ПОЛОЖИТЕЛЬНОГО ПО ФИЛАДЕЛЬФИЙСКОЙ ХРОМОСОМЕ, ИНГИБИТОРАМИ Ab1-ТИРОЗИНКИНАЗЫ
Laudanski Specific or Nonspecific? There Is Very Little Light at the End of the Tunnel
ATE312612T1 (de) Methode zur optimierung der verwendung von 6- mercaptopurin in der behandlung von immun- vermittelten gastrointestinalen störungen